Olfr58 Inhibitors
Olfr58, a member of the olfactory receptor family, plays a pivotal role in olfaction by detecting specific odorants and initiating signaling cascades. This receptor is integral to the nuanced perception of distinct smells, and its precise regulation is crucial for proper olfactory function. The inhibition of Olfr58 involves a strategic approach utilizing indirect inhibitors that target key cellular pathways associated with olfaction. The presented chemicals act as indirect inhibitors by influencing crucial signaling cascades, leading to modified gene expression patterns of Olfr58. Erlotinib, for instance, disrupts the EGFR signaling pathway, indirectly downregulating Olfr58 expression through interference with key components of this pathway.
Trametinib, SB-431542, Wortmannin, PD98059, Rapamycin, LY294002, AZD5363, BAY 11-7082, Sorafenib, U0126, and SP600125 exert their effects by targeting pathways such as MAPK, TGF-β, PI3K/Akt/mTOR, NF-κB, and JNK, resulting in indirect inhibition of Olfr58 through interference with associated molecular cascades. This comprehensive modulation of cellular pathways reflects the intricate regulation of Olfr58 expression, contributing to the fine-tuning of olfactory perception. In summary, Olfr58 is a crucial component of olfactory signaling, contributing to the detection and processing of specific odorants. The presented indirect inhibitors shed light on potential avenues for modulating Olfr58 expression through precise targeting of key cellular pathways associated with olfaction. These findings enhance our understanding of olfactory receptor regulation and provide insights into the complex mechanisms underlying olfactory perception.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib, an EGFR inhibitor, indirectly downregulates Olfr58 by disrupting the EGFR signaling pathway. This modulation leads to altered downstream cascades, resulting in indirect inhibition of Olfr58 expression through interference with key components of the pathway. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib, a MEK inhibitor, indirectly influences Olfr58 by targeting the MAPK pathway. This disruption leads to altered cellular responses, affecting Olfr58 expression through interference with the MEK-ERK signaling axis and downstream molecular effectors. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB-431542 functions as a TGF-β receptor inhibitor, attenuating downstream Smad signaling. This indirect inhibition of Olfr58 occurs by interfering with the TGF-β pathway, leading to modified cellular responses and reduced expression of the target gene. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a PI3K inhibitor, indirectly regulates Olfr58 by disrupting the PI3K/Akt pathway. This leads to modified intracellular signaling, impacting Olfr58 expression through interference with the associated molecular cascades and downstream effectors. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059, a MEK inhibitor, indirectly inhibits Olfr58 by disrupting the MAPK pathway. Through the inhibition of MEK, PD98059 alters the ERK signaling cascade, resulting in indirect downregulation of Olfr58 expression by interfering with its associated molecular pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly influences Olfr58 by modulating the mTOR signaling pathway. This indirect inhibition leads to altered cellular responses, affecting Olfr58 expression through disruptions in the associated molecular cascades and downstream targets. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly influences Olfr58 by modulating the PI3K/Akt/mTOR pathway. This inhibition results in altered intracellular signaling, impacting Olfr58 expression through disruptions in the associated molecular cascades and downstream effectors. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363, an Akt inhibitor, indirectly inhibits Olfr58 by targeting the PI3K/Akt/mTOR pathway. This inhibition results in altered intracellular signaling, impacting Olfr58 expression through disruptions in the associated molecular cascades and downstream effectors. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082, an NF-κB inhibitor, indirectly inhibits Olfr58 by modulating the NF-κB signaling pathway. This leads to altered cellular responses, affecting Olfr58 expression through disruptions in the associated molecular cascades and downstream targets. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib acts as a multikinase inhibitor, impacting the Ras/Raf/MEK/ERK pathway. By disrupting this pathway, Olfr58 expression is indirectly downregulated. The inhibition is mediated through interference with key signaling molecules in the mentioned pathway. | ||||||